Technology development

Several platforms have been established in the laboratory to generate mutation-specific siRNAs or monoclonal antibodies (as described under the p53 section), as well as anti-sense oligonucleotides to alter splicing defects. These are being used to generate reagents against other common genetic alterations in cancers. Furthermore, technologies for targeted delivery to various organs, and for intracellular delivery of siRNAs and antibodies are being pursued.

Other efforts in the laboratory are aimed at developing novel mouse models to study gene functions using CRISPR-technology are also underway.